Tepotinib Gains Full Approval for Metastatic NSCLC

(MedPage Today) -- The FDA transitioned the small-molecule inhibitor tepotinib (Tepmetko) from accelerated to full approval for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. The action occurred after...
Source: MedPage Today Public Health - Category: American Health Source Type: news